XAIR stock Beyond Air (NASDAQ) $2.22 intraday 13 Jan 2026: XTL deal lifts volume
XAIR stock is trading at $2.22 intraday on 13 Jan 2026 after news that XTL Biopharmaceuticals agreed to acquire 85% of Beyond Air’s NeuroNOS subsidiary. The move lifted shares from a previous close of $0.88 to a day high of $2.66 on heavy activity. Volume is extraordinary at 376,345,293.00 shares versus an average of 491,677.00, and traders are pricing the deal impact into NASDAQ-listed Beyond Air, Inc. (United States, USD). We review the catalyst, technicals, valuation and Meyka AI’s forecast for XAIR stock
XAIR stock intraday move and headline catalyst
The main catalyst for the intraday jump is the binding agreement for XTL to acquire 85% of NeuroNOS from Beyond Air, announced 13 Jan 2026. That announcement is tied directly to the price swing: XAIR opened $1.57, recorded a day low of $1.37 and a day high of $2.66, and is trading up 151.16% from the prior close. The transaction includes cash, equity and up to $32.50 million in milestone payments to Beyond Air, which explains why market participants are actively trading the NASDAQ-listed Beyond Air, Inc.
XAIR stock technicals, volume and momentum
Intraday technicals show strong short-term momentum: RSI 33.71, ADX 56.08 indicating a strong trend, and MACD at -0.17 with a slight histogram uptick. On the tape, volume is 376,345,293.00 versus average volume 491,677.00, producing outsized intraday liquidity. The OBV reads 16,595,134.00 and MFI 24.57, consistent with heavy selling earlier and renewed buying on the deal. Traders should note ATR 0.08 and Bollinger middle band $0.93, which underline higher near-term volatility for XAIR stock.
XAIR stock fundamentals and valuation snapshot
Beyond Air, Inc. remains a small-cap healthcare name with market capitalization $4,438,909.00 and 5,067,248.00 shares outstanding. Key ratios: EPS -5.56, PE -0.16, price-to-book 0.44, current ratio 4.24, debt-to-equity 0.93, and cash per share $1.68. Revenue per share is $0.91 but operating cash flow per share is negative $3.72, reflecting ongoing R&D and commercial investment. The company’s year high is $10.40 and year low $0.67, so valuation is volatile and sensitive to corporate-level milestones.
Meyka AI rates XAIR with score and model forecast
Meyka AI rates XAIR with a score out of 100: 61.47 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, analyst consensus and forecasts. Meyka AI’s forecast model projects a 1-year price of $0.94, a 3-year price of $1.64, and a 5-year price of $2.33. Compared with the current price $2.22, the model implies a 5.02% upside to the 5-year projection and a -57.78% change to the 1-year projection. Forecasts are model-based projections and not guarantees. For deal details see the press release and short-interest context: GlobeNewswire press release on XTL deal and MarketBeat short interest update.
XAIR stock outlook, risks and suggested price targets
Near-term price targets: short-term trader target $2.50 (momentum play), 12-month target $1.00 (conservative), 3-year target $1.64 (Meyka 3-year), 5-year target $2.33 (Meyka 5-year). Primary upside driver is milestone payments and value crystallization from the NeuroNOS transaction. Risks include continued negative EPS, cash burn, regulatory outcomes for pipeline programs, and low liquidity outside headline-driven sessions. Given current metrics, investors should treat XAIR stock as high volatility, event-driven exposure and size positions accordingly.
Trading note and resources
XAIR is trading on NASDAQ in the United States with quotes in USD and remains a most-active name intraday due to the XTL transaction. For live updates consult the company site and market data pages and check the Meyka XAIR page for real-time signals. Short interest and trading flows can change rapidly after corporate actions, so use limit orders and watch bid-ask depth on NASDAQ listings.
Final Thoughts
XAIR stock rallied intraday to $2.22 on 13 Jan 2026 after the XTL acquisition of 85% of Beyond Air’s NeuroNOS subsidiary. The jump reflects deal economics that include cash, equity and up to $32.50 million in milestones and triggered a volume spike to 376,345,293.00 shares. Fundamentals remain mixed: EPS -5.56, price-to-book 0.44, and current ratio 4.24 signal balance sheet resilience but ongoing operating losses. Meyka AI’s forecast model sees a 5-year projection of $2.33, implying a 5.02% upside from today’s price, while shorter-term models show downside to $0.94 in 12 months. These contrasting projections underscore that XAIR stock is event-driven and sensitive to regulatory and milestone outcomes. We view the situation as a tradeable, high-volatility scenario for speculative investors; longer-term investors should wait for clearer cash-flow improvements or confirmed milestone receipts. Meyka AI provides this as an AI-powered market analysis platform insight, not investment advice. Forecasts are model-based projections and not guarantees.
FAQs
Why did XAIR stock spike intraday on 13 Jan 2026?
XAIR stock jumped after XTL agreed to buy 85% of Beyond Air’s NeuroNOS subsidiary, including cash, equity and up to $32.50 million in milestones, driving heavy trading and a re-rate of the shares.
What are key valuation metrics for XAIR stock to watch?
Watch EPS -5.56, PE -0.16, price-to-book 0.44, current ratio 4.24, and cash per share $1.68. These show liquidity but persistent operating losses for XAIR stock.
What does Meyka AI forecast imply for XAIR stock?
Meyka AI’s model projects $2.33 in five years, implying about 5.02% upside from $2.22. Models also show a lower 1-year projection near $0.94. Forecasts are projections, not guarantees.
Is XAIR stock suitable for conservative investors?
No. XAIR stock is event-driven and volatile with negative EPS and small market cap. Conservative investors should avoid or keep very small, risk-managed positions.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
